EWA
FDMT icon

EverSource Wealth Advisors’s 4D Molecular Therapeutics FDMT Stock Holding History

EverSource Wealth Advisors’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$532 Sell
40
-3
-7% -$29 ﹤0.01% 4112
2026
Q1 		$401 Buy
43
+11
+34% +$96 ﹤0.01% 4100
2025
Q4 		$240 Hold
32
– – ﹤0.01% 4005
2025
Q3 		$278 Sell
32
-89
-74% -$532 ﹤0.01% 4057
2025
Q2 		$449 Buy
121
+117
+2,925% +$411 ﹤0.01% 3920
2025
Q1 		$13 Buy
+4
New +$19 ﹤0.01% 3985

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

EverSource Wealth Advisors's FDMT Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its 4D Molecular Therapeutics (FDMT) stake by 7% in Q2 2026, selling an estimated $29 and leaving 40 shares worth $532. The position accounts for ﹤0.01% of the portfolio, ranked #4112.

EverSource Wealth Advisors first reported a position in FDMT in Q1 2025 and has held it in 6 quarters since. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • EverSource Wealth Advisors held 40 shares of 4D Molecular Therapeutics worth $532 as of Q2 2026.
  • EverSource Wealth Advisors sold 3 4D Molecular Therapeutics shares in Q2 2026, an estimated $29.
  • 4D Molecular Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #4112 holding.
  • EverSource Wealth Advisors first reported a position in 4D Molecular Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.